Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY 3.25
(0.31%)
CNY 3.25
(0.31%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.76 Billion CNY | 224.01% |
| 2022 | -1.42 Billion CNY | -359.3% |
| 2021 | -309.62 Million CNY | -108.17% |
| 2020 | 3.79 Billion CNY | 117.38% |
| 2019 | 1.74 Billion CNY | -61.68% |
| 2018 | 4.55 Billion CNY | 37.39% |
| 2017 | 3.31 Billion CNY | 2706.79% |
| 2016 | -127.04 Million CNY | -131.28% |
| 2015 | 406.17 Million CNY | -41.49% |
| 2014 | 694.22 Million CNY | 162.33% |
| 2013 | 264.63 Million CNY | 9.4% |
| 2012 | 241.9 Million CNY | 2263.63% |
| 2011 | 10.23 Million CNY | 110.93% |
| 2010 | -93.61 Million CNY | -23.24% |
| 2009 | -75.96 Million CNY | -353.9% |
| 2008 | 29.91 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.06 Billion CNY | -39.74% |
| 2024 Q2 | 3.03 Billion CNY | 185.69% |
| 2024 Q3 | 3.06 Billion CNY | 0.97% |
| 2023 Q3 | -1.64 Billion CNY | 9.34% |
| 2023 FY | 1.76 Billion CNY | 224.01% |
| 2023 Q4 | 1.76 Billion CNY | 207.43% |
| 2023 Q2 | -1.81 Billion CNY | -31.16% |
| 2023 Q1 | -1.38 Billion CNY | 2.92% |
| 2022 Q1 | 34.28 Million CNY | 111.07% |
| 2022 FY | -1.42 Billion CNY | -359.3% |
| 2022 Q4 | -1.42 Billion CNY | -859.4% |
| 2022 Q3 | -148.23 Million CNY | -136.13% |
| 2022 Q2 | 410.22 Million CNY | 1096.49% |
| 2021 FY | -309.62 Million CNY | -108.17% |
| 2021 Q4 | -309.62 Million CNY | -117.96% |
| 2021 Q2 | 2.92 Billion CNY | 3.3% |
| 2021 Q3 | 1.72 Billion CNY | -41.12% |
| 2021 Q1 | 2.83 Billion CNY | -25.21% |
| 2020 Q3 | -24.02 Million CNY | -112.19% |
| 2020 FY | 3.79 Billion CNY | 117.38% |
| 2020 Q1 | 783.31 Million CNY | -55.08% |
| 2020 Q2 | 197.02 Million CNY | -74.85% |
| 2020 Q4 | 3.79 Billion CNY | 15876.18% |
| 2019 Q2 | 1.98 Billion CNY | -12.01% |
| 2019 Q4 | 1.74 Billion CNY | 46.49% |
| 2019 Q3 | 1.19 Billion CNY | -40.15% |
| 2019 FY | 1.74 Billion CNY | -61.68% |
| 2019 Q1 | 2.26 Billion CNY | -50.33% |
| 2018 Q4 | 4.55 Billion CNY | 14.59% |
| 2018 Q3 | 3.97 Billion CNY | -12.94% |
| 2018 Q2 | 4.56 Billion CNY | -30.0% |
| 2018 Q1 | 6.51 Billion CNY | 96.72% |
| 2018 FY | 4.55 Billion CNY | 37.39% |
| 2017 Q1 | 1.02 Billion CNY | 908.68% |
| 2017 Q3 | 2.96 Billion CNY | 69.85% |
| 2017 Q4 | 3.31 Billion CNY | 11.55% |
| 2017 FY | 3.31 Billion CNY | 2706.79% |
| 2017 Q2 | 1.74 Billion CNY | 70.13% |
| 2016 Q1 | 1.14 Billion CNY | 181.04% |
| 2016 FY | -127.04 Million CNY | -131.28% |
| 2016 Q4 | -127.04 Million CNY | 82.64% |
| 2016 Q3 | -731.83 Million CNY | -145.26% |
| 2016 Q2 | 1.61 Billion CNY | 41.65% |
| 2015 Q3 | 623.17 Million CNY | 654.07% |
| 2015 FY | 406.17 Million CNY | -41.49% |
| 2015 Q2 | -112.47 Million CNY | -134.91% |
| 2015 Q4 | 406.17 Million CNY | -34.82% |
| 2015 Q1 | 322.13 Million CNY | -53.6% |
| 2014 Q3 | 741.11 Million CNY | 27.32% |
| 2014 Q1 | 782.72 Million CNY | 195.77% |
| 2014 FY | 694.22 Million CNY | 162.33% |
| 2014 Q4 | 694.22 Million CNY | -6.33% |
| 2014 Q2 | 582.08 Million CNY | -25.63% |
| 2013 Q3 | 636.06 Million CNY | 71.87% |
| 2013 Q4 | 264.63 Million CNY | -58.39% |
| 2013 Q2 | 370.09 Million CNY | 19.73% |
| 2013 FY | 264.63 Million CNY | 9.4% |
| 2013 Q1 | 309.1 Million CNY | 27.78% |
| 2012 Q4 | 241.9 Million CNY | -28.67% |
| 2012 Q3 | 339.1 Million CNY | 59.49% |
| 2012 Q1 | 159.37 Million CNY | 1457.31% |
| 2012 Q2 | 212.61 Million CNY | 33.4% |
| 2012 FY | 241.9 Million CNY | 2263.63% |
| 2011 Q3 | -57.33 Million CNY | 70.28% |
| 2011 Q4 | 10.23 Million CNY | 117.85% |
| 2011 Q1 | 198.69 Million CNY | 312.26% |
| 2011 Q2 | -192.92 Million CNY | -197.09% |
| 2011 FY | 10.23 Million CNY | 110.93% |
| 2010 Q4 | -93.61 Million CNY | 0.0% |
| 2010 FY | -93.61 Million CNY | -23.24% |
| 2009 FY | -75.96 Million CNY | -353.9% |
| 2008 FY | 29.91 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 7.24 Billion CNY | 75.675% |
| Shenzhen Glory Medical Co.,Ltd. | -199.71 Million CNY | 983.013% |